問題 › 競合が顧客を奪っています › ヘルステックおよびデジタルヘルス
競合に顧客を奪われる問題は、多くが成果位置づけの問いであり、シェア喪失とは別の対応が必要です。 デジタルヘルス企業の場合、構造的な難しさがあります。成果リスクの引き受けが、企業がそのリスクを負担可能かを検証できる速度を上回っています。12か月の測定期間に対し、営業サイクルが11か月かかるためです。したがって有効な回答は、収益シェアのリスクとエンゲージメント率を同時に扱う必要がありますが、両者は別システムに存在するため社内分析がここで止まりやすいのです。
競合に顧客を奪われる問題は、多くが成果位置づけの問いであり、シェア喪失とは別の対応が必要です。 デジタルヘルス企業の場合、構造的な難しさがあります。成果リスクの引き受けが、企業がそのリスクを負担可能かを検証できる速度を上回っています。12か月の測定期間に対し、営業サイクルが11か月かかるためです。したがって有効な回答は、収益シェアのリスクとエンゲージメント率を同時に扱う必要がありますが、両者は別システムに存在するため社内分析がここで止まりやすいのです。
競合が勝ち始めると、社内で最初に挙げられる説明は常にリスク負担シェアまたはPMPMです。これは時折正しいですが、多くの場合競合は成果帰属に絞った約束を選び、その中で優位に立っています。営業チームには価格に見えますが、PMPMは失注直前に議論される項目だからです。
この区別は重要です。対応が両立しないためです。リスク負担シェアが本当の問題なら、合わせるか全顧客の価格を再設定するか、そのセグメントの喪失を受け入れるしかありません。位置づけの問題なら、リスク負担シェアを合わせても競合の優位性を強めるだけで粗利益を損ないます。
判断方法は地味です。直近20件の失注理由を成果帰属で区分します。リスク負担シェアの問題なら全体に散らばり、位置づけの問題なら特定の領域に集中します。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ 失注が登録会員全体に均等に広がらず、特定のセグメントまたは用途に集中している
✓ 営業チームが、エンゲージメント率や成果帰属に関する別の証明ではなく、PMPMの引き下げまたはリスク負担シェアの引き上げを求めている
✓ 競合が自社より規模が小さく、特化している
通常、事態を悪化させる対応です。 リスク負担シェアを合わせたうえで位置づけを維持し、粗利益と主張の両方を同時に失うことです。
It is for you if you run or finance a digital health company and losses concentrate in one segment or one use case rather than spreading evenly. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Reduce downside exposure from $7.1M outcomes shortfall to $4.2M while maintaining upside participation in 34 health-plan contracts.
The leak it closes. $2.9M gross profit protected annually through downside cap (difference between $7.1M shortfall at 38% vs $4.2M shortfall at 25%)
The assumption it rests on. Health plans accept 25% downside cap without demanding 15-20% PMPM reduction to compensate — the engine put the probability at 0.7.
| Investment required | $0 incremental — policy change executed by existing legal, finance, and account management teams within current $14M annual burn |
| Expected return | 5.2× on zero incremental investment — derived from $4.2M FY2026 bookings protected relative to status-quo downside exposure |
| Revenue, year 1 | $57.8M ARR (25% at-risk share = $15.5M at-risk revenue vs $23.6M status quo) |
| Revenue, year 2 | $61.4M ARR (assuming 80% contract renewal at 25% cap) |
| Revenue, year 3 | $68.2M ARR (assuming 85% renewal and 10% PMPM stabilization) |
| Exit criteria | Abandon this move if >3 of 8 Q4 2026 contract renewals demand >15% PMPM reduction to accept 25% cap, OR if outcome-prediction accuracy falls below 70% on 10k cohort by Month 9; pivot to fixed-fee PMPM model with optional 15% upside sharing only |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 競合ベンチマークおよび位置づけ, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
その価格でそのセグメントを利益を出して提供でき、すでに高く支払っている顧客の価格も再設定する意思がある場合のみです。選択的な合わせは、市場が気づいた後に守れない約束になりやすいです。
幅ではなく特化で対抗します。資金力の優位な競合はどこでも支出で勝てますが、一つの領域で集中することはできません。約束を絞る方が機能セットを広げるよりも有効です。
正直な回答は、タイムラインと費用を伴う製品判断であり、マーケティングの対応ではありません。メッセージングで埋められない差に1年を費やすことが最も損失の大きい結果です。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית